Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2014, for Trxade Group, Inc. (Note: The input metadata referenced "Scienture Holdings," but the filing text explicitly identifies the registrant as Trxade Group, Inc.). The Company operates a B2B web-based marketplace for the US pharmaceutical industry, connecting independent pharmacies with suppliers. It also owns Westminster Pharmaceutical LLC (pharmaceutical supply) and Pinnacle Tek, Inc. (IT consulting). The Company is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2014 | Six Months Ended June 30, 2013 |
|---|---|---|
| Revenues | $531,913 | $430,821 |
| Gross Profit | $333,937 | $108,144 |
| Gross Margin | 62.8% | 25.1% |
| Operating Loss | $(644,547) | $(368,163) |
| Net Loss | $(1,223,016) | $(369,084) |
| Cash and Equivalents (End of Period) | $70,485 | $11,814 |
| Working Capital | $(82,310) | $112,263 |
| Short-Term Debt (Related Parties) | $62,750 | $72,722 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased by approximately 23% year-over-year, driven primarily by fee income from the web-based platform and new client acquisition.
- Margin Expansion: Gross margin improved significantly from 25.1% to 62.8%. This was due to a shift in revenue mix toward the lower-cost web platform and reduced transaction volume in the higher-cost Westminster Pharmaceutical division.
- Expense Increase: General and Administrative (G&A) expenses rose to $978,484 (six months) from $476,307. This increase is attributed to professional fees (legal, accounting, SEC filing) required to become a fully reporting company and increased payroll for operational staffing.
- Non-Cash Loss: A significant non-cash loss on debt conversion of $576,417 was recorded in 2014. This resulted from converting a $19,333 related-party loan into 600,000 shares of common stock valued at $600,000.
- Liquidity Position: Working capital turned negative ($82,310 deficit) compared to a positive $112,263 in the prior year, driven by increases in accounts payable and accrued liabilities (primarily management wages).
Guidance, Outlook, and Risks
- Capital Requirements: Management estimates operating expenses and working capital needs for the next 12 months to be approximately $2.65 million ($600k Cost of Sales, $2.05M G&A). Current cash of ~$70k is insufficient, necessitating additional equity or debt financing.
- Operational Focus: The Company plans to continue developing the Trxade platform, expanding the client base, and launching the "RxGuru" desktop application for data analytics.
- Controls and Procedures: Management concluded that disclosure controls and procedures were not effective as of June 30, 2014.
- Subsequent Events: In July and August 2014, 150,000 additional Series A Preferred Shares were issued. Upon becoming a reporting company in August 2014, all 1,045,000 Series A Preferred Shares automatically converted to common stock on a 1:1 basis.
- Risks: The Company faces risks related to its ability to raise capital, continued unprofitability, and the potential dilution of existing shareholders.
Investor Verification Checklist
- Capital Adequacy: Verify the Company's ability to raise the estimated $2.65 million required for the next 12 months given the current cash balance of only $70,485.
- Debt Conversion Impact: Confirm the valuation methodology used for the $576,417 loss on debt conversion and its impact on the net loss figure.
- Revenue Quality: Assess the sustainability of the revenue growth from the web platform versus the pharmaceutical supply arm.
- Internal Controls: Review the specific material weaknesses identified in the disclosure controls and procedures.
- Related Party Transactions: Monitor the balance of related-party debt ($62,750) and the terms of future advances from officers and board members.